JMKX003002
/ Jemincare
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 03, 2025
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
(clinicaltrials.gov)
- P2 | N=50 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease
October 29, 2024
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: Jemincare
New P2 trial • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease
June 18, 2023
Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Jemincare
New P1 trial
1 to 3
Of
3
Go to page
1